Professor, Biochemistry and Molecular Genetics
- PhD, Molecular Cell Biology, University of Tokyo
- Postdoc, Cancer Biology, Harvard Medical School
Biochemistry, Cancer Biology, Epigenetics, Experimental Pathology, Genetics, Molecular Biology, Molecular Pharmacology
Cell signaling, hematopoietic stem cell biology, molecular and epigenetic mechanisms of leukemia.
My laboratory focuses on understanding the molecular and epigenetic mechanisms involved in the regulation of normal hematopoiesis and hematologic malignancies. The ultimate goal of our research is to identify new therapeutic targets and develop novel therapeutic strategies for treatment of leukemia. JAK2, a member of the Janus family of non-receptor protein tyrosine kinases, is activated in response to a variety of cytokines. A somatic JAK2V617F mutation has been found in a majority of patients with myeloproliferative neoplasms (MPNs). One of the major interests in our lab is to study the role of the JAK/STAT signaling in the pathogenesis of MPNs. We are also investigating the interaction of epigenetic modulators with the JAK2 mutation in MPNs using state-of-the-art techniques and genetically engineered animal models.
Current research projects in my laboratory are focused in the following areas:
(1) Elucidation of the role of JAK2 and JAK2V617F mutation in hematopoiesis and myeloproliferative neoplasms (MPNs).
(2) Investigation of the role of SHP2 in MPNs, and targeting of SHP2 in MPNs using SHP2-specific inhibitors.
(3) Investigation of the role of protein tyrosine phosphatase PTPN1 in myeloid neoplasms.
(4) Investigation of the role of histone methyltransferase EZH2 in the pathogenesis of myelofibrosis (MF).
(5) Testing the efficacy of potential new targeted therapies for MPNs using novel animal models.